Clinical Trial Detail

NCT ID NCT02775435
Title A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Nab-paclitaxel

Pembrolizumab

Carboplatin + Paclitaxel

Age Groups: adult

No variant requirements are available.